"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
As an adjunct in the short-term treatment of pain accompanied by tension and/or anxiety in patients with musculoskeletal disease. Clinical trials have demonstrated that in these situations relief of pain is somewhat greater than with aspirin alone. The effectiveness of Equagesic (meprobamate and aspirin) in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient
DOSAGE AND ADMINISTRATION
The usual dosage of Equagesic (meprobamate and aspirin) is one or two tablets, each tablet containing meprobamate, 200 mg, and aspirin, 325 mg, orally 3 to 4 times daily as needed for the relief of pain when tension or anxiety is present. Equagesic (meprobamate and aspirin) is not recommended for patients 12 years of age and under.
Equagesic (meprobamate and aspirin) ® (meprobamate with aspirin) Tablets, 200 mg meprobamate and 325 mg aspirin, are available as follows:
NDC 0008-0091, pink and yellow, double-layer, round, scored tablet marked "WYETH" and "91", in bottles of 100 tablets.
Store at room temperature, approx. 25o C (77o F). Keep tightly closed. Protect from light. Dispense in light-resistant, tight container.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Equagesic Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.